
Please try another search
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Name | Age | Since | Title |
---|---|---|---|
Garry A. Nicholson | 70 | 2022 | Chairman of the Board & Lead Independent Director |
Daniel Curran | 58 | - | Board Observer |
John A. Josey | 64 | 2020 | Independent Director |
Sona Saira Gonsalves Ramasastry | 49 | 2021 | Independent Director |
David S. Grayzel | 57 | - | Board Observer |
Natalie C. Holles | 52 | 2021 | Independent Director |
Jeremy Bender | 54 | 2020 | CEO, President & Director |
William J. Grossman | 54 | 2024 | Independent Director |
Scott Garland | 56 | 2021 | Independent Director |
Habib Joseph Dable | 56 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review